The Part D program is funded through a variety of government subsidies and manufacturer discounts. The federal reinsurance, initially designed as protection from catastrophic spending, became a primary source of subsidies for the program. When the Inflation Reduction Act (IRA) is fully implemented in 2025, the funding of Part D will realign to its original intent.
By attending this session, you will be able to:
• Learn how the IRA changes how prescription drugs are funded Discover what the potential impact to member premiums is and how the 6% cap on premiums can apply
• Understand how the IRA will rebalance the government's direct subsidy and federal reinsurance
• Explore the change to Manufacturer Discount program and how it will impact the different types of drugs
• Decipher the new incentives for the major stakeholders